The patent has been granted The patent has been granted, Grant of patent is intended, Examination is in progress, Request for examination was made EP Register Verified

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

Publication No. EP4458350

•

App No. EP24197314

•

Filed by Translate Bio, Inc.

•

Filed on 2012-06-08

•

Issued/Published on 2025-12-24

Official EPO Register

Publication No. EP4458350 A2

Application No. EP24197314 Filed: 2012-06-08

Grant Date 2025-12-24 Mention of grant

Active Oppositions 7 Active EPO Oppositions

Patent Abstract / Summary

Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.

IPC Classifications

A61K31/713, A61K9/127, A61K48/00, A61K47/44, A61P3/00, A61K9/1272, A61P5/00, C07K14/505, C07K14/81, C12N9/64, C12N15/52, C12N15/88, A61P7/06 A61K31/713, A61K48/00, A61K47/44, A61P3/00 A61K9/127

Priority Claims

US 201161494881P Date: 2011-06-08

Designated Contracting States (38 EPC States)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Parties & Representation

Applicants

Translate Bio, Inc.

200 West Street, Waltham, MA 02451

Inventors (3)

GUILD, Braydon Charles

Concord, 01742

DEROSA, Frank

Chelmsford, 01824

HEARTLEIN, Michael

Boxborough, 01719

Representatives / Agents

Carpmaels & Ransford LLP

One Southampton Row, London WC1B 5HA

Pfizer

European Patent Department, 23-25 avenue du Docteur Lannelongue

J A Kemp LLP

80 Turnmill Street, London EC1M 5QU

Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB

Weinstraße 8, 80333 München

Maiwald GmbH

Elisenhof, Elisenstraße 3

Mewburn Ellis LLP

Aurora Building, Counterslip

Willems, Marie Anne P, et al

GSK, Legal & Compliance - Global Patents

Key Procedural Dates

Request-For-Examination 2024-08-29

Mention Of Grant Published 2025-12-24

First-Examination-Report-Despatched 2025-01-09

Patent Oppositions

Official opposition proceedings filed against European Patent EP4458350 under EPC Article 99.

7 ACTIVE OPPONENTS

Opponent Company

Pfizer Inc.

66 Hudson Boulevard East, US

Representative

Pfizer

Filing Date

2026-09-23

Opposition in Progress

Opponent Company

Merck Sharp & Dohme LLC

P.O. Box 2000, US

Representative

J A Kemp LLP

Filing Date

2026-09-24

Opposition in Progress

Opponent Company

Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB/ Blodig, Wolfgang

Weinstrasse 8, DE

Representative

Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB

Filing Date

2026-09-24

Opposition in Progress

Opponent Company

Strawman Limited

Office 9, Dalton House, GB

Representative

Maiwald GmbH

Filing Date

2026-09-24

Opposition in Progress

Opponent Company

Margaret Dixon Limited

1st Floor, Aurora Building, GB

Representative

Mewburn Ellis LLP

Filing Date

2026-09-24

Opposition in Progress

Opponent Company

GlaxoSmithKline Biologicals SA

Rue de l'Institut 89, BE

Representative

Willems, Marie Anne P, et al

Filing Date

2026-09-24

Opposition in Progress

Opponent Company

Maiwald GmbH

Elisenhof, DE

Representative

Maiwald GmbH

Filing Date

2026-09-24

Opposition in Progress

Legal Status & Event History

Official European Patent Office legal and procedural status changes recorded for this file.

58 Events Recorded

Date	Code	Event Description	Auth
2024-11-06	17P	REQUEST FOR EXAMINATION FILED	EP
2024-11-06	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2024-11-06	AK	DESIGNATED CONTRACTING STATES	EP
2024-10-03	PUAI	PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE	EP
2024-10-03	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2024-12-20	PUAL	SEARCH REPORT DESPATCHED	EP
2024-12-16	REG	REFERENCE TO A NATIONAL CODE	EP
2025-01-10	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-01-22	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-01-22	AK	DESIGNATED CONTRACTING STATES	EP
2025-02-12	17Q	FIRST EXAMINATION REPORT DESPATCHED	EP
2025-08-08	REG	REFERENCE TO A NATIONAL CODE	EP
2025-11-16	GRAP	DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT	EP
2025-11-16	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-11-21	GRAA	(EXPECTED) GRANT	EP
2025-11-20	GRAS	GRANT FEE PAID	EP
2025-11-21	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-12-03	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-12-17	INTG	INTENTION TO GRANT ANNOUNCED	EP
2025-12-24	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2025-12-24	AK	DESIGNATED CONTRACTING STATES	EP
2025-12-24	REG	REFERENCE TO A NATIONAL CODE	EP
2026-01-08	REG	REFERENCE TO A NATIONAL CODE	EP
2026-01-12	REG	REFERENCE TO A NATIONAL CODE	EP
2026-01-28	P01	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED	EP
2026-02-02	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-10	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-13	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-14	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-17	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-17	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-28	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-30	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-29	REG	REFERENCE TO A NATIONAL CODE	EP
2026-05-15	REG	REFERENCE TO A NATIONAL CODE	EP
2026-05-18	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-06-29	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-01	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-03	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-09	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-09	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-10	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-11	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-15	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-16	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-17	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-18	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-21	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-23	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-25	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-08-06	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-09-25	PLBI	OPPOSITION FILED	EP
2026-09-30	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-02	PLAB	OPPOSITION DATA, OPPONENT'S DATA OR THAT OF THE OPPONENT'S REPRESENTATIVE MODIFIED	EP
2026-09-23	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-07	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-11	PLAX	NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATION + TIME LIMIT SENT	EP
2026-10-10	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP

Patent & Non-Patent Citations

Cited documents and prior art referenced in search and examination reports.

168 Citations

Cited Patent Documents

US201261617468 2012-03-29

Espacenet

US201161494745 2011-06-08

Espacenet

US83528197

Espacenet

US60083294

Espacenet

US201161494882 2011-06-08

Espacenet

US6066626

Espacenet

US2004110709

Espacenet

US2009286852

Espacenet

US2003083272

Espacenet

US5677124

Espacenet

US4920016

Espacenet

WO2010053572

Espacenet

US4897355

Espacenet

US5171678

Espacenet

US5334761

Espacenet

WO2010042877

Espacenet

WO2005121348

Espacenet

US5744335

Espacenet

US5885613

Espacenet

US4737323

Espacenet

WO2007024708 2007-03-01

Espacenet

WO2011068810 2011-06-09

Espacenet

US26565309

Espacenet

US37882610

Espacenet

US37883110

Espacenet

US36183010

Espacenet

US37883710

Espacenet

US36182810

Espacenet

US36178010

Espacenet

US39196010

Espacenet

US36179410

Espacenet

US36178910

Espacenet

US37883310

Espacenet

US201261648244

Espacenet

US201161494881

Espacenet

US61505088

Espacenet

US201161529878

Espacenet

WO2005120152 2005-12-22

Espacenet

WO2012031043 2012-03-08

Espacenet

WO2012030901 2012-03-08

Espacenet

WO2012006378 2012-01-12

Espacenet

WO2011005799 2011-01-13

Espacenet

WO2009086558 2009-07-09

Espacenet

WO2011008974

Espacenet

WO2012006376

Espacenet

WO2012006372

Espacenet

WO2012051211

Espacenet

WO2010105209

Espacenet

WO9851278

Espacenet

WO2009082817

Espacenet

WO2011012316

Espacenet

US2012195936

Espacenet

WO2012006369

Espacenet

WO2012006377

Espacenet

WO2012031046

Espacenet

WO0000617

Espacenet

WO2010088537

Espacenet

EP2113247

Espacenet

WO2013090648

Espacenet

WO2012170930

Espacenet

US6287591

Espacenet

WO2013006825

Espacenet

WO2013033563

Espacenet

US2003077829

Espacenet

US2006134189

Espacenet

US2010267806

Espacenet

US2010324120

Espacenet

US9233145

Espacenet

Non-Patent Scientific Literature (NPL)

- X. SU ET AL., MOL. PHARMACEUTICS, vol. 8, 2011, pages 774 - 787

- KOZAK, M., NUCLEIC ACIDS RES, vol. 15, no. 20, 1987, pages 8125 - 48

- HEIDENREICH ET AL., J BIOL CHEM, vol. 269, 1994, pages 2131 - 8

- KARIKÓ, K. ET AL., MOLECULAR THERAPY, vol. 16, no. 11, 2008, pages 1833 - 1840

- YOKOE ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 1252 - 1256

- KRIEG ET AL., MELTON. METHODS IN ENZYMOLOGY, vol. 155, 1987, pages 397 - 415

- LIEBHABER., J. MOL. BIOL., vol. 226, 1992, pages 2 - 13

- MONIA ET AL., J BIOL CHEM., vol. 268, 1993, pages 14514 - 22

- LASIC, TRENDS BIOTECHNOL, vol. 16, 1998, pages 307 - 321

- DRUMMOND ET AL., PHARMACOL. REV., vol. 51, 1999, pages 691 - 743

- LASIC, TRENDS BIOTECHNOL., vol. 16, 1998, pages 307 - 321

- LASIC ET AL., FEBS LETT., vol. 312, 1992, pages 255 - 258

- N.J. CAPLEN ET AL., GENE THER., vol. 2, 1995, pages 603

- S. LI ET AL., , GENE THER., vol. 1997, no. 4, pages 891

- FELGNER ET AL., PROC. NAT'L ACAD. SCI., vol. 84, 1987, pages 7413

- BEHR ET AL., PROC. NAT.'L ACAD. SCI., vol. 86, 1989, pages 6982

- SEMPLE ET AL., NATURE BIOTECH., vol. 28, 2010, pages 172 - 176

- HEYES, J. ET AL., J CONTROLLED RELEASE, vol. 107, 2005, pages 276 - 287

- MORRISSEY, DV. ET AL., NAT. BIOTECHNOL., vol. 23, no. 8, 2005, pages 1003 - 1007

- GAO ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 179, 1991, pages 280

- WOLF ET AL., BIOTECHNIQUES, vol. 23, 1997, pages 139

- KLIBANOV ET AL., FEBS LETTERS, vol. 268, no. 1, 1990, pages 235 - 237

- BLOOMFIELD, ANN. REV. BIOPHYS. BIOENG., vol. 10, 1981, pages 421 - 450

- HILLERY AM ET AL.: "Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists", 2002, TAYLOR & FRANCIS, INC.

- FECHTEBROWNLEE, J. GEN. VIROLOGY, vol. 86, 2005, pages 1239 - 1249

- MICHAEL J. PASSINEAU ET AL: "[alpha]-Galactosidase A Expressed in the Salivary Glands Partially Corrects Organ Biochemical Deficits in the Fabry Mouse Through Endocrine Trafficking", HUMAN GENE THERAPY, vol. 22, no. 3, 1 March 2011 (2011-03-01), pages 293 - 301, XP055478144, ISSN: 1043-0342, DOI: 10.1089/hum.2010.069

- AKIN AKINC ET AL: "A combinatorial library of lipid-like materials for delivery of RNAi therapeutics", NATURE BIOTECHNOLOGY, vol. 26, no. 5, 27 April 2008 (2008-04-27), New York, pages 561 - 569, XP055533621, ISSN: 1087-0156, DOI: 10.1038/nbt1402

- LIU YANG ET AL: "Designer Lipids Advance Systemic siRNA Delivery", MOLECULAR THERAPY, vol. 18, no. 4, April 2010 (2010-04-01), pages 669 - 670, XP002684383, ISSN: 1525-0016

- SEAN C SEMPLE ET AL: "Rational design of cationic lipids for siRNA delivery", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 28, no. 2, 1 February 2010 (2010-02-01), pages 172 - 176, XP002633693, ISSN: 1087-0156, [retrieved on 20100117], DOI: 10.1038/NBT.1602

- GEERTRUI TAVERNIER ET AL: "mRNA as gene therapeutic: How to control protein expression", JOURNAL OF CONTROLLED RELEASE, vol. 150, no. 3, 1 March 2011 (2011-03-01), pages 238 - 247, XP055068617, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2010.10.020

- K. T. LOVE ET AL: "Lipid-like materials for low-dose, in vivo gene silencing", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 5, 2 February 2010 (2010-02-02), pages 1864 - 1869, XP055077922, ISSN: 0027-8424, DOI: 10.1073/pnas.0910603106

- AKINC A ET AL: "Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver", MOLECULAR THERAPY,, vol. 17, no. 5, 1 May 2009 (2009-05-01), pages 872 - 879, XP008105983, ISSN: 1525-0016, [retrieved on 20090303], DOI: 10.1038/MT.2009.36

- KOYNOVA RUMIANA ET AL: "Recent patents in cationic lipid carriers for delivery of nucleic acids", RECENT PATENTS ON DNA & GENE SEQUENCES, BENTHAM SCIENCE, UNITED ARAB EMIRATES, vol. 5, no. 1, 1 January 2011 (2011-01-01), pages 8 - 27, XP009170736, ISSN: 2212-3431, DOI: 10.2174/187221511794839255

- XINGFANG SU: "In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles", MOLECULAR PHARMACEUTICS, vol. 8, no. 3, 21 March 2011 (2011-03-21), US, pages 774 - 787, XP093167466, ISSN: 1543-8384, DOI: 10.1021/mp100390w

- "Handbook of Pharmaceutical Biotechnology", 1 June 2007, JOHN WILEY & SONS , ISBN: 978-0-471-21386-4, article SHAYNE COX, STEVE PASCOLO: "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", pages: 971 - 1011, XP055626043, DOI: 10.1002/9780470117118.ch07b * Pages 971-1011 *

- SHIRAZI RAHAU S., EWERT KAI K., LEAL CECILIA, MAJZOUB RAMSEY N., BOUXSEIN NATHAN F., SAFINYA CYRUS R.: "Author manuscript: Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1808, no. 9, 1 September 2011 (2011-09-01), AMSTERDAM, NL , pages 1 - 25, XP093439748, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2011.04.020 * pages 2156–2166. *

- FRÉDÉRIC MARTINON, SIVADASAN KRISHNAN, GERLINDE LENZEN, RÉMY MAGNÉ, ELISABETH GOMARD, JEAN-GÉRARD GUILLET, JEAN-PAUL LÉVY, PIERRE : "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, vol. 23, no. 7, 1 July 1993 (1993-07-01), Hoboken, USA, pages 1719 - 1722, XP002937540, ISSN: 0014-2980, DOI: 10.1002/eji.1830230749 * pages 1719-1722 *

- JAMES HEYES, LORNE PALMER, KAZ BREMNER, IAN MACLACHLAN: "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, NL, vol. 107, no. 2, 3 October 2005 (2005-10-03), NL , pages 276 - 287, XP008157522, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2005.06.014 * pages 276-287 *

- LLOYD B. JEFFS ; LORNE R. PALMER ; ELLEN G. AMBEGIA ; CORY GIESBRECHT ; SHANNON EWANICK ; IAN MACLACHLAN: "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 22, no. 3, 1 March 2005 (2005-03-01), NL , pages 362 - 372, XP019370801, ISSN: 1573-904X, DOI: 10.1007/s11095-004-1873-z * pages 362-372 *

- FRICKE, J. ; SEUNG, E. ; VASSOR, V. ; TAGER, A.M. ; GANDHI, R.T. ; WALKER, B. ; IRVINE, D. ; KAVANAGH, D.: "Synthetic mRNA-loaded Nanoparticles Elicit Mucosal IL-17+ and IFNγ+ T Cells", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 135, no. Supplement, 1 January 2010 (2010-01-01), AMSTERDAM, NL , pages S137, XP027049215, ISSN: 1521-6616, DOI: 10.1016/j.clim.2010.03.416

- CROOKE STANLEY T: "ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED.", 1 January 2007, CRC PRESS , US , ISBN: 978-0-8493-8796-8, article MACLACHLAN I.: "Liposomal formulations for nucleic acid delivery", pages: 237 - 270, XP002584305

- YOU CHANGJUN, DAI XIAOXIA, WANG YINSHENG: "Position-dependent effects of regioisomeric methylated adenine and guanine ribonucleosides on translation", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD., ENGLAND, vol. 45, no. 15, 6 September 2017 (2017-09-06), England, pages 9059 - 9067, XP093439754, ISSN: 0305-1048, DOI: 10.1093/nar/gkx515

- AEBISCHER MEGANE K.; TSALMPOURIS ATHANASIOS; RUDAZ SERGE; MALBURET CAMILLE; COTTE JEAN-FRANÇOIS; GUILLARME DAVY; MAURER JONATHAN: "Two-dimensional AEX – IP-RPLC: New insights on mRNA integrity and encapsulation efficiency of mRNA-lipid nanoparticle formulations", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1394, 7 February 2026 (2026-02-07), AMSTERDAM, NL , XP087987625, ISSN: 0003-2670, DOI: 10.1016/j.aca.2026.345215

- ANITA BRINGMANN, STEFANIE ANDREA ERIKA HELD, ANNKRISTIN HEINE, PETER BROSSART: "RNA Vaccines in Cancer Treatment", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, HINDAWI PUB. CORP., vol. 2010, pages 1 - 12, XP002765542, ISSN: 1110-7243, DOI: 10.1155/2010/623687

- DONG YIZHOU, SIEGWART DANIEL J., ANDERSON DANIEL G.: "Author manuscript: Strategies, design, and chemistry in siRNA delivery systems", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 144, 1 April 2019 (2019-04-01), Amsterdam , NL , pages 1 - 30, XP093439778, ISSN: 0169-409X, DOI: 10.1016/j.addr.2019.05.004

- JIRIKOWSKI GUSTAV F., PIETRO PAOLO SANNA, DOMINIQUE MACIEJEWSKI-LENOIR, AND FLOYD E. BLOOM: "Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 255, no. 5047, 21 February 1992 (1992-02-21), US , pages 996 - 998, XP093439780, ISSN: 0036-8075, DOI: 10.1126/science.1546298

- W-Z ZHOU, D S B HOON, S K S HUANG, ET AL: "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 10, no. 16, 1 November 1999 (1999-11-01), GB , pages 2719 - 2724, XP002660042, ISSN: 1043-0342, DOI: 10.1089/10430349950016762

- MICHAEL S D KORMANN, GÜNTHER HASENPUSCH, MANISH K ANEJA, GABRIELA NICA, ANDREAS W FLEMMER, SUSANNE HERBER-JONAT, MARCELINE HUPPMAN: "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 29, no. 2, 1 February 2011 (2011-02-01), New York, pages 154 - 157, XP055040839, ISSN: 1087-0156, DOI: 10.1038/nbt.1733

- KARIKÓ K, MURAMATSU H, KELLER J M, WEISSMAN D.: "Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 20, no. 5, 1 May 2012 (2012-05-01), GB , pages 948 - 953, XP002696191, ISSN: 1525-0024, DOI: 10.1038/mt.2012.7

- RAYNER J O, DRYGA S A, KAMRUD K I: "ALPHAVIRUS VECTORS AND VACCINATION", REVIEWS IN MEDICAL VIROLOGY, CHICHESTER, GB, vol. 12, no. 05, 1 September 2002 (2002-09-01), GB , pages 279 - 296, XP008035758, ISSN: 1052-9276, DOI: 10.1002/rmv.360

- WEISS RICHARD; SCHEIBLHOFER SANDRA; ROESLER ELISABETH; FERREIRA FATIMA; THALHAMER JOSEF: "Prophylactic mRNA vaccination against allergy", CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, US, vol. 10, no. 6, 1 December 2010 (2010-12-01), US , pages 567 - 574, XP009164452, ISSN: 1528-4050, DOI: 10.1097/ACI.0b013e32833fd5b6

- SIBERT BRYAN S., KIM JOSEPH Y., YANG JIE E., KE ZUNLONG, STOBART CHRISTOPHER C., MOORE MARTIN L., WRIGHT ELIZABETH R.: "Assembly of respiratory syncytial virus matrix protein lattice and its coordination with fusion glycoprotein trimers", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 15, no. 1, 14 July 2024 (2024-07-14), UK, pages 5923 - 13, XP093439799, ISSN: 2041-1723, DOI: 10.1038/s41467-024-50162-x

- J. SAENZ-BADILLOS, S. P. AMIN, R. D. GRANSTEIN: "RNA as a tumor vaccine: a review of the literature", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 10, no. 3, 1 June 2001 (2001-06-01), COPENHAGEN; DK , pages 143 - 154, XP055244457, ISSN: 0906-6705, DOI: 10.1034/j.1600-0625.2001.010003143.x

- SAXENA, S. ; SONWANE, A.A. ; DAHIYA, S.S. ; PATEL, C.L. ; SAINI, M. ; RAI, A. ; GUPTA, P.K.: "Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 136, no. 1-2, 14 April 2009 (2009-04-14), NL , pages 36 - 44, XP026071306, ISSN: 0378-1135, DOI: 10.1016/j.vetmic.2008.10.030

- KARIKÓ KATALIN, MURAMATSU HIROMI, WELSH FRANK A, LUDWIG JÁNOS, KATO HIROKI, AKIRA SHIZUO, WEISSMAN DREW: "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", MOLECULAR THERAPY, ELSEVIER INC, UNITED STATES, vol. 16, no. 11, 1 November 2008 (2008-11-01), United States, pages 1833 - 1840, XP093147613, ISSN: 1525-0016, DOI: 10.1038/mt.2008.200

- ZOU, S. ; SCARFO, K. ; NANTZ, M.H. ; HECKER, J.G.: "Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 389, no. 1-2, 15 April 2010 (2010-04-15), AMSTERDAM, NL, pages 232 - 243, XP026933138, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2010.01.019

- YAMAMOTO A. ET AL: "Current prospects for mRNA gene delivery", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 71, no. 3, 1 March 2009 (2009-03-01), NL , pages 484 - 489, XP025992169, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2008.09.016

- TRACY S ZIMMERMANN, AMY C H LEE, AKIN AKINC, BIRGIT BRAMLAGE, DAVID BUMCROT, MATTHEW N FEDORUK, JENS HARBORTH, JAMES A HEYES, LLOY: "RNAi-mediated gene silencing in non-human primates.", NATURE, SPRINGER SCIENCE AND BUSINESS MEDIA LLC, LONDON, vol. 441, no. 7089, 4 May 2006 (2006-05-04), London, pages 111 - 114, XP002577898, ISSN: 0028-0836, DOI: 10.1038/NATURE04688

- SEMPLE, S.C. KLIMUK, S.K. HARASYM, T.O. DOS SANTOS, N. ANSELL, S.M. WONG, K.F. MAURER, N. STARK, H. CULLIS, P.R. HOPE, M.J. SCHERR: "Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1510, no. 1-2, 9 February 2001 (2001-02-09), AMSTERDAM, NL , pages 152 - 166, XP004248775, ISSN: 0005-2736, DOI: 10.1016/S0005-2736(00)00343-6

- SANDRA K. KLIMUK, SEAN C. SEMPLE, PATRICK N. NAHIRNEY, MICHELLE C. MULLEN, C. FRANK BENNETT, PETER SCHERRER, MICHAEL J. HOPE: "Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, ELSEVIER INC, UNITED STATES, vol. 292, no. 2, 1 February 2000 (2000-02-01), United States, pages 480 - 488, XP002336134, ISSN: 0022-3565, DOI: 10.1016/S0022-3565(24)35316-9

- AKINC AKIN ET AL: "A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 26, no. 5, 1 May 2008 (2008-05-01), New York, pages 561 - 569, XP002577899, ISSN: 1087-0156, DOI: 10.1038/NBT1402

- LOVE KEVIN T., MAHON KERRY P., LEVINS CHRISTOPHER G., WHITEHEAD KATHRYN A., QUERBES WILLIAM, DORKIN J. ROBERT, QIN JUNE, CANTLEY W: "SUPPORTING INFORMATION: Lipid-like materials for low-dose, in vivo gene silencing", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 5, 2 February 2010 (2010-02-02), pages 1864 - 1869, XP093088665, ISSN: 0027-8424, DOI: 10.1073/pnas.0910603106

- K. T. LOVE, K. P. MAHON, C. G. LEVINS, K. A. WHITEHEAD, W. QUERBES, J. R. DORKIN, J. QIN, W. CANTLEY, L. L. QIN, T. RACIE, M. FRAN: "Lipid-like materials for low-dose, in vivo gene silencing", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 5, 2 February 2010 (2010-02-02), pages 1864 - 1869, XP055077922, ISSN: 00278424, DOI: 10.1073/pnas.0910603106

- HEIJNE VON G: "THE SIGNAL PEPTIDE", JOURNAL OF MEMBRANE BIOLOGY, SPRINGER NEW YORK LLC, US, vol. 115, no. 03, 1 May 1990 (1990-05-01), US , pages 195 - 201, XP009011512, ISSN: 0022-2631, DOI: 10.1007/BF01868635

- PASCOLO STEVE: "Vaccination with messenger RNA (mRNA)", TOLL-LIKE RECEPTORS (TLRS) AND INNATE IMMUNITY, BERLIN [U.A.] : SPRINGER, DE, vol. 183, 1 January 2008 (2008-01-01), DE , pages 221 - 235, XP001538300, ISBN: 978-3-540-72166-6, DOI: 10.1007/978-3-540-72167-3_11

- D WEISSMAN, H NI, D SCALES, A DUDE, J CAPODICI, K MCGIBNEY, A ABDOOL, S N ISAACS, G CANNON, K KARIKÓ: "HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., vol. 165, no. 8, 1 January 2000 (2000-01-01), pages 4710 - 4717, XP008051732, ISSN: 0022-1767, DOI: 10.4049/jimmunol.165.8.4710

- DE FOUGEROLLES ANTONIN R: "Delivery vehicles for small interfering RNA in vivo", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 19, no. 2, 1 February 2008 (2008-02-01), GB , pages 125 - 132, XP002522155, ISSN: 1043-0342, DOI: 10.1089/HUM.2008.928

- B. OZPOLAT, SOOD A. K., LOPEZ-BERESTEIN G.: "Nanomedicine based approaches for the delivery of siRNA in cancer", JOURNAL OF INTERNAL MEDICINE, BLACKWELL PUBLISHING LTD, GB, vol. 267, no. 1, 1 January 2009 (2009-01-01), GB , pages 44 - 53, XP055242950, ISSN: 0954-6820, DOI: 10.1111/j.1365-2796.2009.02191.x

- GEERTRUI TAVERNIER, OLIWIA ANDRIES, JO DEMEESTER, NIEK N. SANDERS, STEFAAN C. DE SMEDT, JOANNA REJMAN: "mRNA as gene therapeutic: How to control protein expression", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, vol. 150, no. 3, 1 March 2011 (2011-03-01), pages 238 - 247, XP055068617, ISSN: 01683659, DOI: 10.1016/j.jconrel.2010.10.020

- MELISSA A. TRAN, REBECCA J. WATTS, GAVIN P. ROBERTSON: "Use of liposomes as drug delivery vehicles for treatment of melanoma", PIGMENT CELL & MELANOMA RESEARCH, WILEY INTERSCIENCE, UNITED STATES, DENMARK, vol. 22, no. 4, 1 August 2009 (2009-08-01), United States, Denmark , pages 388 - 399, XP055299784, ISSN: 1755-1471, DOI: 10.1111/j.1755-148X.2009.00581.x

- KAWAKAMI M, TSUTSUMI H, KUMAKAWA T, ABE H, HIRAI M, KUROSAWA S, MORI M, FUKUSHIMA M: "Levels of serum granulocyte colony-stimulating factor in patients with infections", BLOOD, ELSEVIER INC, UNITED STATES, vol. 76, no. 10, 15 November 1990 (1990-11-15), United States, pages 1962 - 1964, XP093439847, ISSN: 0006-4971, DOI: 10.1182/blood.v76.10.1962.bloodjournal76101962

- FOX ELIZABETH, WIDEMANN BRIGITTE C., HAWKINS DOUGLAS S., JAYAPRAKASH NALINI, DAGHER RAMZI, AIKIN ALBERTA A., BERNSTEIN DONNA, LONG: "Author manuscript: Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH INC, vol. 15, no. 23, 1 December 2009 (2009-12-01), pages 1 - 18, XP093439851, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-09-0761

- KAY M A, LANDEN C N, ROTHENBERG S R, TAYLOR L A, LELAND F, WIEHLE S, FANG B, BELLINGER D, FINEGOLD M, THOMPSON A R: "In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 91, no. 6, 15 March 1994 (1994-03-15), pages 2353 - 2357, XP093439855, ISSN: 0027-8424, DOI: 10.1073/pnas.91.6.2353

- D64 - Submission of the Applicant of 9 May 2025 filed during prosecution of EP 24 197 314.8 (the application underlying EP’350).

- D65 - Submission of the Applicant of 2 September 2025 filed during prosecution of EP 24 197 314.8 (the application underlying EP’350).

- GUO X, SZOKA F C: "CHEMICAL APPROACHES TO TRIGGERABLE LIPID VESICLES FOR DRUG AND GENE DELIVERY", ACCOUNTS OF CHEMICAL RESEARCH, ACS , WASHINGTON , DC, US, vol. 36, no. 05, 1 May 2003 (2003-05-01), US , pages 335 - 341, XP001161617, ISSN: 0001-4842, DOI: 10.1021/ar9703241

- HITOMI HIROFUMI, KASAHARA TOMOKO, KATAGIRI NAOKO, HOSHINA AZUSA, MAE SHIN-ICHI, KOTAKA MAKI, TOYOHARA TAKAFUMI, RAHMAN ASADUR, NAK: "Human pluripotent stem cell–derived erythropoietin-producing cells ameliorate renal anemia in mice", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 9, no. 409, 27 September 2017 (2017-09-27), pages eaaj2300 - 16, XP093439861, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaj2300

- LONG XU, THOMAS ANCHORDOQUY: "Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid-based therapeutics", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, vol. 100, no. 1, 1 January 2011 (2011-01-01), pages 38 - 52, XP055044014, ISSN: 00223549, DOI: 10.1002/jps.22243

- FANG J, ET AL: "Stable antibody expression at therapeutic levels using the 2A peptide.", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 23, no. 5, 17 April 2005 (2005-04-17), New York, pages 584 - 590, XP002369310, ISSN: 1087-0156, DOI: 10.1038/nbt1087

- D71 - T0197/22 (Delivery of mRNA II/TRANSLATE BIO)

- AKINC A., ET AL: "Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver", MOLECULAR THERAPY, ELSEVIER INC, UNITED STATES, vol. 17, no. 5, 1 May 2009 (2009-05-01), United States, pages 872 - 879, XP008105983, ISSN: 1525-0016, DOI: 10.1038/MT.2009.36

- KOYNOVA RUMIANA; TENCHOV BORIS: "Recent patents in cationic lipid carriers for delivery of nucleic acids.", RECENT PATENTS ON DNA & GENE SEQUENCES, BENTHAM SCIENCE, UNITED ARAB EMIRATES, vol. 5, no. 1, 1 January 2011 (2011-01-01), United Arab Emirates , pages 8 - 27, XP009170736, ISSN: 2212-3431, DOI: 10.2174/187221511794839255

- SCHROEDER A., LEVINS C. G., CORTEZ C., LANGER R., ANDERSON D. G.: "Author manuscript: Lipid‐based nanotherapeutics for siRNA delivery", JOURNAL OF INTERNAL MEDICINE, BLACKWELL PUBLISHING LTD, GB, vol. 267, no. 1, 14 February 2017 (2017-02-14), GB , pages 1 - 21, XP093439869, ISSN: 0954-6820, DOI: 10.1111/j.1365-2796.2009.02189.x

- SEAN C SEMPLE, AKIN AKINC, JIANXIN CHEN, AMMEN P SANDHU, BARBARA L MUI, CONNIE K CHO, DINAH W Y SAH, DERRICK STEBBING, ERIN J CROS: "Rational design of cationic lipids for siRNA delivery", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 28, no. 2, 1 February 2010 (2010-02-01), New York, pages 172 - 176, XP002633693, ISSN: 1087-0156, DOI: 10.1038/NBT.1602

- YAN, X. KUIPERS, F. HAVEKES, L.M. HAVINGA, R. DONTJE, B. POELSTRA, K. SCHERPHOF, G.L. KAMPS, J.A.A.M.: "The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 328, no. 1, 4 March 2005 (2005-03-04), Amsterdam NL , pages 57 - 62, XP004723739, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2004.12.137

- AKIN AKINC, WILLIAM QUERBES, SOMA DE, JUNE QIN, MARIA FRANK-KAMENETSKY, K. NARAYANANNAIR JAYAPRAKASH, MUTHUSAMY JAYARAMAN, KALLANT: "Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 18, no. 7, 1 July 2010 (2010-07-01), pages 1357 - 1364, XP055016290, ISSN: 15250016, DOI: 10.1038/mt.2010.85

- JUDGE ADAM D ET AL: "Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, UNITED STATES, vol. 119, no. 3, 1 March 2009 (2009-03-01), United States, pages 661 - 673, XP002618489, ISSN: 0021-9738, DOI: 10.1172/JCI37515

- EGRIE JOAN C, DWYER ERIK, BROWNE JEFFREY K, HITZ ANNA, LYKOS MICHELE A: "Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC., US, vol. 31, no. 4, 1 April 2003 (2003-04-01), US , pages 290 - 299, XP093440002, ISSN: 0301-472X, DOI: 10.1016/s0301-472x(03)00006-7

- FRIED, W.: "Erythropoietin and erythropoiesis", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC., US, vol. 37, no. 9, 1 September 2009 (2009-09-01), US , pages 1007 - 1015, XP026459229, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2009.05.010

- NEY PAUL A: "Author manuscript: Normal and disordered reticulocyte maturation", CURRENT OPINION IN HEMATOLOGY, RAPID SCIENCE PUBLISHERS, PHILADELPHIA, PA., US, vol. 18, no. 3, 1 May 2012 (2012-05-01), US , pages 1 - 12, XP093440006, ISSN: 1065-6251, DOI: 10.1097/moh.0b013e328345213e

- VAN PUTTEN L., CROON FINEKE: "The Life Span of Red Cells in the Rat and the Mouse as Determined by Labeling with DFP32 in Vivo", BLOOD, ELSEVIER INC, UNITED STATES, vol. 13, no. 8, 1 August 1958 (1958-08-01), United States, pages 789 - 794, XP093440008, ISSN: 0006-4971, DOI: 10.1182/blood.v13.8.789.789

- R. T. PETERS, S. C. LOW, G. D. KAMPHAUS, J. A. DUMONT, J. V. AMARI, Q. LU, G. ZARBIS-PAPASTOITSIS, T. J. REIDY, E. P. MERRICKS, T.: "Prolonged activity of factor IX as a monomeric Fc fusion protein", BLOOD, vol. 115, no. 10, 11 March 2010 (2010-03-11), pages 2057 - 2064, XP055087904, ISSN: 00064971, DOI: 10.1182/blood-2009-08-239665

- JONES E. A., VERGALLA J., STEER C. J., BRADLEY-MOORE P. R., VIERLING J. M.: "Metabolism of Intact and Desialylated α1-Antitrypsin", CLINICAL SCIENCE., BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 55, no. 2, 1 August 1978 (1978-08-01), GB , pages 139 - 148, XP093440010, ISSN: 0143-5221, DOI: 10.1042/cs0550139

- NURIA PADULLES, ZAMORA RAFAEL, VIDAL PIA, GISPERT PILAR, RIO DEL, MARGALEFF ROSENDO JARDI, FRIAS FRANCISCO RODRIGUEZ, BRUONO JOSE,: "Intravenous Human Plasma-Derived Augmentation Therapy in a.-Antitrypsin Deficiency: From Pharmacokinetic Analysis to Individualizing Therapy", ANNALS OF PHARMACOTHERAPY, SAGE PUBLICATIONS, LOS ANGELES, CA, vol. 42, no. 5, 1 May 2008 (2008-05-01), Los Angeles, CA, pages 640 - 646, XP093440014, ISSN: 1060-0280, DOI: 10.1345/aph.1K505

- SUDA TAKESHI, KAMIMURA KENYA, KUBOTA TOMOYUKI, TAMURA YASUSHI, IGARASHI MASATO, KAWAI HIROKAZU, AOYAGI YUTAKA, LIU DEXI: "Progress toward liver‐based gene therapy", HEPATOLOGY RESEARCH, AMSTERDAM, NL, vol. 39, no. 4, 1 April 2009 (2009-04-01), NL , pages 325 - 340, XP093440015, ISSN: 1386-6346, DOI: 10.1111/j.1872-034x.2008.00479.x

- YU XIAOBING; LIN CHYUAN-SHENG; COSTANTINI FRANK; NOGUCHI CONSTANCE TOM: "The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse", BLOOD, AMSTERDAM, NL, vol. 98, no. 2, 15 July 2001 (2001-07-15), AMSTERDAM, NL, pages 475 - 477, XP086704274, DOI: 10.1182/blood.V98.2.475

- G. L. SEMENZA, TRAYSTMAN MONICA D, GEARHARTT JOHN D, ANTONARAKIS STYLIANOS E: "Polycythemia in transgenic mice expressing the human erythropoietin gene.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 86, no. 7, 1 April 1989 (1989-04-01), pages 2301 - 2305, XP055233828, ISSN: 0027-8424, DOI: 10.1073/pnas.86.7.2301

- JOERG SCHUETTRUMPF, ET AL.: "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, vol. 105, no. 6, 15 March 2005 (2005-03-15), pages 2316 - 2323, XP055542043, DOI: 10.1182/blood-2004-08-2990

- OGAWA SHINGO, ONODERA JUN, HONDA RIKA, FUJIMOTO ICHIRO: "Influence of systemic administration of atelocollagen on mouse livers: an ideal biomaterial for systemic drug delivery", THE JOURNAL OF TOXICOLOGICAL SCIENCES, TOKYO., JP, vol. 36, no. 6, 1 December 2011 (2011-12-01), JP , pages 751 - 762, XP093440017, ISSN: 0388-1350, DOI: 10.2131/jts.36.751

Worldwide Patent Family

Related applications and patents in the same INPADOC worldwide family.

121 Family Members

Country	Publication Number	Kind	Publication Date	Action
EP	EP4458350A2	A2	2024-11-06	Espacenet
EP	EP4458350A3	A3	2025-01-22	Espacenet
EP	EP4458350B1	B1	2025-12-24	Espacenet
AU	AU2012267531A1	A1	2013-12-19	Espacenet
AU	AU2012267531B2	B2	2017-06-22	Espacenet
AU	AU2017204509A1	A1	2017-07-20	Espacenet
AU	AU2017204509B2	B2	2019-04-11	Espacenet
AU	AU2017204509C1	C1	2019-07-25	Espacenet
AU	AU2019201924A1	A1	2019-04-11	Espacenet
AU	AU2019201924B2	B2	2021-04-08	Espacenet
AU	AU2021204597A1	A1	2021-07-29	Espacenet
AU	AU2024278311A1	A1	2025-01-09	Espacenet
BR	BR112013031553A2	A2	2020-11-10	Espacenet
CA	CA2838069A1	A1	2012-12-13	Espacenet
CA	CA2838069C	C	2021-10-12	Espacenet
CA	CA3107288A1	A1	2012-12-13	Espacenet
CL	CL2013003478A1	A1	2014-07-04	Espacenet
CN	CN103906527A	A	2014-07-02	Espacenet
CN	CN103906527B	B	2020-07-10	Espacenet
CN	CN111671918A	A	2020-09-18	Espacenet
CN	CN111671919A	A	2020-09-18	Espacenet
CY	CY1122123T1	T1	2020-11-25	Espacenet
DK	DK2717893T3	T3	2019-07-22	Espacenet
DK	DK3586861T3	T3	2022-04-25	Espacenet
DK	DK4458350T3	T3	2026-02-02	Espacenet
EP	EP2717893A1	A1	2014-04-16	Espacenet
EP	EP2717893B1	B1	2019-05-08	Espacenet
EP	EP3586861A1	A1	2020-01-01	Espacenet
EP	EP3586861B1	B1	2022-02-09	Espacenet
EP	EP4043025A1	A1	2022-08-17	Espacenet
ES	ES2740248T3	T3	2020-02-05	Espacenet
ES	ES2911653T3	T3	2022-05-20	Espacenet
ES	ES3063637T3	T3	2026-04-17	Espacenet
HK	HK1199206A1	A1	2015-06-26	Espacenet
HR	HRP20191338T1	T1	2019-10-18	Espacenet
HU	HUE044277T2	T2	2019-10-28	Espacenet
IL	IL229699B	B	2021-02-28	Espacenet
IL	IL280771A	A	2021-04-29	Espacenet
IL	IL280771B1	B1	2023-11-01	Espacenet
IL	IL280771B2	B2	2024-03-01	Espacenet
IL	IL307511A	A	2023-12-01	Espacenet
JP	JP2014523411A	A	2014-09-11	Espacenet
JP	JP6184945B2	B2	2017-08-23	Espacenet
JP	JP2017014278A	A	2017-01-19	Espacenet
JP	JP6372042B2	B2	2018-08-15	Espacenet
JP	JP2017203045A	A	2017-11-16	Espacenet
JP	JP6463810B2	B2	2019-02-06	Espacenet
JP	JP2019048900A	A	2019-03-28	Espacenet
JP	JP6752299B2	B2	2020-09-09	Espacenet
JP	JP2020186266A	A	2020-11-19	Espacenet
JP	JP7645058B2	B2	2025-03-13	Espacenet
JP	JP2023087094A	A	2023-06-22	Espacenet
JP	JP2026050449A	A	2026-03-19	Espacenet
KR	KR20140044356A	A	2014-04-14	Espacenet
KR	KR102128248B1	B1	2020-07-01	Espacenet
KR	KR20200084048A	A	2020-07-09	Espacenet
KR	KR20220025112A	A	2022-03-03	Espacenet
KR	KR20240135871A	A	2024-09-12	Espacenet
LT	LT2717893T	T	2019-08-12	Espacenet
ME	ME03491B	B	2020-01-20	Espacenet
MX	MX2013014419A	A	2014-01-23	Espacenet
MX	MX367605B	B	2019-08-28	Espacenet
MX	MX2019010226A	A	2019-10-15	Espacenet
MX	MX421064B	B	2025-02-10	Espacenet
NZ	NZ618275A	A	2016-11-25	Espacenet
NZ	NZ719345A	A	2023-03-31	Espacenet
NZ	NZ734700A	A	2023-01-27	Espacenet
NZ	NZ745686A	A	2022-09-30	Espacenet
PE	PE20140797A1	A1	2014-07-11	Espacenet
PL	PL2717893T3	T3	2019-12-31	Espacenet
PL	PL3586861T3	T3	2022-05-23	Espacenet
PT	PT2717893T	T	2019-08-20	Espacenet
PT	PT3586861T	T	2022-04-21	Espacenet
RS	RS59037B1	B1	2019-08-30	Espacenet
RU	RU2013154295A	A	2015-07-20	Espacenet
SI	SI2717893T1	T1	2019-10-30	Espacenet
SM	SMT201900445T1	T1	2019-09-09	Espacenet
TR	TR201910686T4	T4	2019-08-21	Espacenet
US	US2017239371A1	A1	2017-08-24	Espacenet
US	US10238754B2	B2	2019-03-26	Espacenet
US	US2019192689A1	A1	2019-06-27	Espacenet
US	US10350303B1	B1	2019-07-16	Espacenet
US	US2019175761A1	A1	2019-06-13	Espacenet
US	US10413618B2	B2	2019-09-17	Espacenet
US	US2019321489A1	A1	2019-10-24	Espacenet
US	US10507249B2	B2	2019-12-17	Espacenet
US	US2020338214A1	A1	2020-10-29	Espacenet
US	US10888626B2	B2	2021-01-12	Espacenet
US	US2021060177A1	A1	2021-03-04	Espacenet
US	US11052159B2	B2	2021-07-06	Espacenet
US	US2021300755A1	A1	2021-09-30	Espacenet
US	US11185595B2	B2	2021-11-30	Espacenet
US	US2022040330A1	A1	2022-02-10	Espacenet
US	US11291734B2	B2	2022-04-05	Espacenet
US	US2022105201A1	A1	2022-04-07	Espacenet
US	US11338044B2	B2	2022-05-24	Espacenet
US	US2022111070A1	A1	2022-04-14	Espacenet
US	US11547764B2	B2	2023-01-10	Espacenet
US	US2022111072A1	A1	2022-04-14	Espacenet
US	US11730825B2	B2	2023-08-22	Espacenet
US	US2023285592A1	A1	2023-09-14	Espacenet
US	US11951179B2	B2	2024-04-09	Espacenet
US	US2023285593A1	A1	2023-09-14	Espacenet
US	US11951180B2	B2	2024-04-09	Espacenet
US	US2023330262A1	A1	2023-10-19	Espacenet
US	US11951181B2	B2	2024-04-09	Espacenet
US	US2022378939A1	A1	2022-12-01	Espacenet
US	US12121592B2	B2	2024-10-22	Espacenet
US	US2014206753A1	A1	2014-07-24	Espacenet
US	US2014294938A1	A1	2014-10-02	Espacenet
US	US9308281B2	B2	2016-04-12	Espacenet
US	US2014294939A1	A1	2014-10-02	Espacenet
US	US9597413B2	B2	2017-03-21	Espacenet
US	US2020085973A1	A1	2020-03-19	Espacenet
US	US2022111071A1	A1	2022-04-14	Espacenet
US	US2022362406A1	A1	2022-11-17	Espacenet
US	US2023293723A1	A1	2023-09-21	Espacenet
US	US20250108126A1	A1	2025-04-03	Espacenet
US	US20250152735A1	A1	2025-05-15	Espacenet
WO	WO2012170930A1	A1	2012-12-13	Espacenet
WO	WO2012170930A9	A9	2014-01-03	Espacenet

Official File Inspection EPC Art. 128 Public Dossier

Complete European Patent Register Dossier (148 Total Documents)

The full inspection file for Application EP24197314 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.

Open 148-Doc Register Dossier

Recorded Filings & Patent Specifications

Official publication specifications, opposition filings, proprietor replies, and procedural submissions.

41 Filings Listed

European Patent Specification - Granted Patent (B1)

Publication Specification

Date: 2025-12-24 Procedure: Grant EP4458350B1

View / Download PDF

Official European Patent Register Full Dossier

Publication Specification

Date: 2025-12-24 Procedure: All Proceedings (Examination & Opposition) EP24197314

View / Download PDF

European Search Report (A3)

Publication Specification

Date: 2025-01-22 Procedure: Publication EP4458350A3

View / Download PDF

European Patent Application without Search Report (A2)

Publication Specification

Date: 2024-11-06 Procedure: Publication EP4458350A2

View / Download PDF

Invitation to proprietor to file observations on the notice of opposition

Procedural Step

Date: 2026-10-12 Procedure: Opposition OBSO

Inspect on Register

New entry: Communication of a notice of opposition and request to file observations + time limit

Dossier Filing

Date: 2026-10-11 Procedure: Opposition EPIDOSNOBS2

Inspect on Register

Change - opposition data/opponent's data or that of the opponent's representative

Dossier Filing

Date: 2026-10-02 Procedure: Opposition 0009299OPPO

Inspect on Register

Opposition filed

Dossier Filing

Date: 2026-09-25 Procedure: Opposition 0009260

Inspect on Register

Lapse of the patent in a contracting state

Dossier Filing

Date: 2026-08-07 Procedure: Examination 0009250

Inspect on Register

Lapse of the patent in a contracting state

Dossier Filing

Date: 2026-07-31 Procedure: Examination 0009250

Inspect on Register

Lapse of the patent in a contracting state

Dossier Filing

Date: 2026-05-22 Procedure: Examination 0009250

Inspect on Register

Lapse of the patent in a contracting state

Dossier Filing

Date: 2026-05-08 Procedure: Examination 0009250

Inspect on Register

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

Patent Abstract / Summary

IPC Classifications

Priority Claims

Designated Contracting States (38 EPC States)

Parties & Representation

Applicants

Inventors (3)

Representatives / Agents

Key Procedural Dates

Patent Oppositions

Pfizer Inc.

Merck Sharp & Dohme LLC

Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB/ Blodig, Wolfgang

Strawman Limited

Margaret Dixon Limited

GlaxoSmithKline Biologicals SA

Maiwald GmbH

Legal Status & Event History

Patent & Non-Patent Citations

Cited Patent Documents

Non-Patent Scientific Literature (NPL)

Worldwide Patent Family

Complete European Patent Register Dossier (148 Total Documents)

Recorded Filings & Patent Specifications

European Patent Specification - Granted Patent (B1)

Official European Patent Register Full Dossier

European Search Report (A3)

European Patent Application without Search Report (A2)

Invitation to proprietor to file observations on the notice of opposition

New entry: Communication of a notice of opposition and request to file observations + time limit

Change - opposition data/opponent's data or that of the opponent's representative

Opposition filed

Lapse of the patent in a contracting state

Lapse of the patent in a contracting state

Lapse of the patent in a contracting state

Lapse of the patent in a contracting state

(Expected) grant

New entry: Payment of fee for grant

New entry: Payment of fee for publishing/printing

New entry: Receipt of the translation of the claim(s)

Intention to grant the patent

New entry: Communication of intention to grant a patent

Change - classification

New entry: Reply to examination report

New entry: Despatch of examination report + time limit

Communication from the examining division

New entry: Reply to examination report

New entry: Renewal fee paid

Renewal fee payment

First examination report

New entry: Despatch of examination report + time limit

Communication from the examining division

Change - classification

Publication of search report

Date on which the examining division has become responsible

The date on which the examining division becomes responsible, has been established

Publication in section I.1 EP Bulletin

Request for examination filed

New entry: Fee payment for extension state

Change - representative

New entry: Renewal fee paid

Renewal fee payment

Extension of the patent

Language of the procedure

International searching authority